Safety, Tolerability and Immunogenicity of Meningococcal B Recombinant Vaccine Administered With or Without Routine Infant Vaccinations to Healthy Infants According to Different Immunization Schedules

NCT00721396 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

1885

Enrollment

INDUSTRY

Sponsor class

Conditions

Meningococcal Infections

Interventions

BIOLOGICAL: rMenB+OMV NZ
BIOLOGICAL: combined diphtheria,tetanus,pertussis+polio+Hepatitis B+Haemophilus influenzae B vaccine
BIOLOGICAL: Pneumococcal vaccine

Sponsor

Novartis Vaccines